Morgan Stanley upgraded Waterdrop from Equal-Weight to Overweight and set a new price target of $2.10 from $2.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/16/2022 | $2.00 → $2.10 | Equal-Weight → Overweight | Morgan Stanley |
| 3/25/2022 | $5.00 → $2.00 | Overweight → Equal-Weight | Morgan Stanley |
SC 13G/A - Waterdrop Inc. (0001823986) (Subject)
SC 13G/A - Waterdrop Inc. (0001823986) (Subject)
SC 13G/A - Waterdrop Inc. (0001823986) (Subject)
BEIJING, Dec. 12, 2024 /PRNewswire/ -- On December 11, 2024, Waterdrop Inc. (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, unveiled its unaudited financial results for the third quarter of 2024 ended September 30, 2024. During the quarter, Waterdrop reported net operating revenue of RMB 704.1 million. Net profit attributable to ordinary shareholders totaled RMB 92.8 million, up 152.6% from the previous year, sustaining profitability for the eleventh consecutive quarter. Operating expenses, including sales, administrative, and R&D costs, accounted for 47.9% of revenue, a decrease of 6.9 percentage points year-on-year. S
BEIJING, Dec. 11, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and nine months ended September 30, 2024. Financial and Operational Highlights for the Third Quarter of 2024 Marked improvement in profitability and healthy liquidity: In the third quarter of 2024, net profit attributable to our ordinary shareholders reached RMB92.8 million, representing a year-over-year growth of 152.6%. As of September 30, 2024, we continued to generate positive operating cash flow during the third quarte
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics, today announced successful completion of an $42 million Series A financing. The financing round was led by Lanchi Ventures, a preeminent global early-stage technology investor known for backing breakthrough innovations, with participation from an elite syndicate of new investors including Yuanbio Venture Capital, Legend Capital and C&D Emergin
BEIJING, Dec. 11, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and nine months ended September 30, 2024. Financial and Operational Highlights for the Third Quarter of 2024 Marked improvement in profitability and healthy liquidity: In the third quarter of 2024, net profit attributable to our ordinary shareholders reached RMB92.8 million, representing a year-over-year growth of 152.6%. As of September 30, 2024, we continued to generate positive operating cash flow during the third quarte
BEIJING, Nov. 27, 2024 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2024, before U.S. markets open on Wednesday, December 11, 2024. Waterdrop's management team will hold a conference call on December 11, 2024 at 7:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows: International: 1-412-317-6061 United States Toll Free: 1-888-317-6
BEIJING, Sept. 4, 2024 /PRNewswire/ -- On September 4, 2024, Waterdrop Inc. (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, unveiled its unaudited financial results for the second quarter of 2024 ended June 30, 2024. During the quarter, Waterdrop reported net operating revenue of RMB 676 million. Net profit attributable to ordinary shareholders totaled RMB 88.3 million, up 306.9% from the previous year, sustaining profitability for the tenth consecutive quarter. Operating expenses, including sales, administrative, and R&D costs, accounted for 45.1% of revenue, a decrease of 12 percentage points year-on-year. In addition
6-K - Waterdrop Inc. (0001823986) (Filer)
6-K - Waterdrop Inc. (0001823986) (Filer)
6-K - Waterdrop Inc. (0001823986) (Filer)
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics, today announced the successful completion of a $42 million Series A financing. The financing round was led by Lanchi Ventures, a preeminent global early-stage technology investor known for backing breakthrough innovations, with participation from an elite syndicate of new investors including Yuanbio Venture Capital, Legend Capital and C&D Eme
BEIJING, Jan. 22, 2024 (GLOBE NEWSWIRE) -- QuantaSing Group Limited (NASDAQ:QSG) ("QuantaSing" or the "Company"), today announced the appointment of a new independent director and a change to the audit committee of the Company's board of directors (the "Audit Committee"). Mr. Chenyang Wei was appointed as an independent director of the Company and as a member of the Audit Committee, effective on January 22, 2024. Mr. Chenyang Wei has served as the Associate Dean of Institute for Fintech Research, Tsinghua University and Director of China Insurance and Pension Research Center, the National Institute of Financial Research, Tsinghua University PBC School of Finance since April 2019. From De
BEIJING, March 17, 2023 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced the appointment of Mr. Wei Ran as a new director to its board of directors (the "Board") and the resignation of Mr. Yao Hu from the Board, effective March 17, 2023. After the change, the Board will consist of nine members, three of whom are independent directors. Mr. Hu's resignation does not involve any disagreement with the Company with regard to its business, finance, accounting or any other affairs. Concurrently with the Board change, the Company brings in new memb
Morgan Stanley upgraded Waterdrop from Equal-Weight to Overweight and set a new price target of $2.10 from $2.00 previously
Morgan Stanley downgraded Waterdrop from Overweight to Equal-Weight and set a new price target of $2.00 from $5.00 previously